anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of budesonide capsules (enteric coated) have been established in pediatric patients 8 to 17 years of age who weigh more than 25 kg for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. Use of budesonide capsules (enteric coated) in this age group is supported by evidence from adequate and well controlled studies of budesonide capsules (enteric coated) in adults, with additional data from 2 clinical studies in 149 pediatric patients treated up to 8 weeks and one pharmacokinetic study in 8 pediatric patients [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)] . 

The observed safety profile of budesonide capsules (enteric coated) in pediatric patients is consistent with its known safety profile in adults and no new safety concerns were identified [see Adverse Reactions (6.1)] . 

Systemic corticosteroids, including budesonide capsules (enteric coated), may cause a reduction of growth velocity in pediatric patients. Pediatric patients with Crohn's disease have a 17% higher mean systemic exposure and cortisol suppression than adults with Crohn's disease [see Warning and Precautions (5.1) and Clinical Pharmacology (12.2)] . 

The safety and effectiveness of budesonide capsules (enteric coated) have not been established in pediatric patients less than 8 years of age for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon.

The safety and effectiveness of budesonide capsules (enteric coated) have not been established in pediatric patients for the maintenance of clinical remission of mild to moderate Crohn's disease. An open-label study to evaluate the safety and tolerability of budesonide capsules (enteric coated) as maintenance treatment in pediatric patients aged 5 to 17 years was conducted, and did not establish the safety and efficacy of maintenance of clinical remission.
A method for delivering at least one drug at a target site in a blood vessel for treating at least one of an acute myocardial infarction, a thrombus containing lesion and a saphenous-vein graft lesion is disclosed. The method includes delivering nano-carriers at the target site. The nano-carriers include one or more drugs encapsulated with a first biological agent. The nano-carriers further include a second biological agent in contact with one or more of the first biological agent and the one or more drugs. The first biological agent and the second biological agent have a first dissolution rate and a second dissolution rate respectively. The first dissolution rate is different from the second dissolution rate. The one or more drugs are released at the target site from the nano- carriers at a first release rate and a second release rate in response to dissolution of the first biological agent and the second biological agent, respectively.
Glioblastoma (GBM) is the most common primary malignant brain tumor. Despite great efforts have been devoted to promoting the treatment effect, GBM remains one of the most lethal tumors concurrent with poor prognosis and inevitable recurrence. The standard treatment protocol for GBM includes surgical resection, radiotherapy and temozolomide (TMZ) based chemotherapy. TMZ, an alkylating agent, has been proved to be efficient to control tumor growth after surgery and gradually has been recognized in routine clinical course for GBM. In a pivotal clinical trial published in 2005, GBM patients received concomitant TMZ and radiotherapy followed by 6 periods of adjuvant TMZ chemotherapy had a median survival of 14.6 months and 5-year survival rate of 9.8%, which has been regarded as a landscape in treatment history of GBM. To date, this regimen remains the standard protocol for newly diagnosed GBM patients. However, the optimal timing of initiation of TMZ or radiotherapy remains unclear. Our previous study showed 75mg per square meter of body surface per day (mg/m2/d) of TMZ chemotherapy alone was effective to control post-operative edema caused by tumor cell infiltration in primary GBM patients. The result suggested anti-cancer agents such as TMZ may be a useful regimen to control tumor cell regrowth after operation. Therefore, we conducted this prospective clinical trial to testify the hypothesis that supra-early initiation of TMZ chemotherapy in newly diagnosed GBM patients is effective to control tumor growth after tumor resection and therefore improve patients'clinical outcome.
OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of \~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
Krabbe disease (KD) is an autosomal recessive neurodegenerative disorder caused by deficiency of the galactocerebrosidase (GALC) due to variants in the GALC gene. Here, we provide the first and the largest comprehensive analysis of clinical and genetic characteristics, and genotype-phenotype correlations of KD in Korean in comparison with other ethnic groups. From June 2010 to June 2023, 10 patients were diagnosed with KD through sequencing of GALC. Clinical features, and results of GALC sequencing, biochemical test, neuroimaging, and neurophysiologic test were obtained from medical records. An additional nine previously reported Korean KD patients were included for review. In Korean KD patients, the median age of onset was 2 years (3 months-34 years) and the most common phenotype was adult-onset (33%, 6/18) KD, followed by infantile KD (28%, 5/18). The most frequent variants were c.683_694delinsCTC (23%) and c.1901T>C (23%), while the 30-kb deletion was absent. Having two heterozygous pathogenic missense variants was associated with later-onset phenotype. Clinical features were similar to those of other ethnic groups. In Korean KD patients, the most common phenotype was the adult-onset type and the GALC variant spectrum was different from that of the Caucasian population. This study would further our understanding of KD.
Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the "Book of Life", which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously.
It is an object of the invention to improve a user's breathing for a specific application (e.g. diagnostic imaging, falling asleep improvement (shortening sleep onset), delivery, tinnitus control therapy, CORD, blood pressure control). This object is achieved by a breathing adaptation system configured for influencing a breathing parameter of a user's breathing pattern in order to meet a goal of decreasing or increasing the influenced breathing parameter to a certain extent in a user specific manner. The breathing adaptation system comprises a sensor, configured for monitoring a current value of the influenced breathing parameter of the user. The breathing adaptation system further comprises a feedback unit configured for providing feedback to the user about a preferred value of the influenced breathing parameter, wherein the preferred value is different from the current value of the influenced breathing parameter ( 310 ). The breathing adaptation system further comprises a control unit, comprising program code means for determining the preferred value of the influenced breathing parameter in a user specific manner by means of an intelligent agent, wherein the control unit is implemented such that the intelligent agent is rewarded ( 330 ) by means of a reward function after performing the determination of the preferred value ( 320 ) of the influenced breathing parameter, wherein the reward function is such that it balances the reward for obtaining the goal and the ability of the user to breathe according to a breathing pattern having the preferred value for the influenced breathing parameter.
The goal of this registry is to collect information on individuals with rhizomelic chondrodysplasia punctata (also called RCDP). This registry will enable detailed natural history studies of RCDP, with the hopes that identification of risk factors will allow for preventative treatments and thus a better quality of life for individuals with these diagnoses.

This study is limited to chart review, after signed informed consent obtained. There will be no additional visits or time in clinic because of participation in this registry. This study involves only the collection and storage of data extracted from the medical record. Records that may be requested and reviewed as a part of this study include but may not be limited to: specialist evaluations, surgical reports, results of blood and urine tests, genetic testing, x-rays, CT/MRI imaging. There are no special procedures, visits, or expectations of the individual as a result of participation in this registry. No one will be asked to have any specific testing for the sole purposes of this research.
This comprehensive review delineates the extensive roles of Akkermansia muciniphila in various health domains, spanning from metabolic and inflammatory diseases to neurodegenerative disorders. A. muciniphila, known for its ability to reside in the mucous layer of the intestine, plays a pivotal role in maintaining gut integrity and interacting with host metabolic processes. Its influence extends to modulating immune responses and potentially easing symptoms across several non-communicable diseases, including obesity, diabetes, inflammatory bowel disease, and cancer. Recent studies highlight its capacity to interact with the gut-brain axis, suggesting a possible impact on neuropsychiatric conditions. Despite the promising therapeutic potential of A. muciniphila highlighted in animal and preliminary human studies, challenges remain in its practical application due to stability and cultivation issues. However, the development of pasteurized forms and synthetic mediums offers new avenues for its use in clinical settings, as recognized by regulatory bodies like the European Food Safety Authority. This narrative review serves as a crucial resource for understanding the broad implications of A. muciniphila across different health conditions and its potential integration into therapeutic strategies.
Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
The invention relates to the preparation of aerosol compositions. The invention provides a method for the preparation of liposomes in which at least two separate components are brought together under pressure, a first component comprising water and a second component comprising a lipid material. The components are then passed as a mixture under pressure through a nozzle or other arrangement to produce an aerosol spray containing liposomes. In addition, at least one of the first or second components preferably includes a separate active material. The invention also provides a pack for use in preparing a liposomal aerosol comprising at least a first and a second chamber, one chamber containing a first component comprising water and the other chamber containing a second component comprising a lipid material, and one or both of the chambers and/or a third chamber including a propellant material. The pack also includes an arrangement for dispensing as a spray a mixture of the first and second components fed from their respective chambers under pressure developed by the propellant material or materials.
BACKGROUND: Intraprostatic local radiorecurrence (LRR) after definitive radiation is being increasingly identified due to the implementation of molecular positron emission tomography (PET)/computed tomography (CT) imaging for the evaluation of biochemical recurrence. Salvage high-dose rate (HDR) brachytherapy offers a promising local therapy option, with encouraging toxicity and efficacy based on early series. Furthermore, the incorporation of advanced imaging allows for focal HDR to further reduce toxicity to maximise the therapeutic ratio. The objectives of the 'focal salvage HDR brachytherapy for locally recurrent prostate cancer in patients treated with prior radiotherapy' (F-SHARP) trial are to determine the acute and late toxicity and efficacy outcomes of focal salvage HDR brachytherapy for LRR prostate cancer.
STUDY DESIGN: The F-SHARP is a multi-institutional two-stage Phase I/II clinical trial of salvage focal HDR brachytherapy for LRR prostate cancer enrolling patients at three centres.
ENDPOINTS: The primary endpoint is the acute radiation-related Grade ≥3 Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) genitourinary (GU) and gastrointestinal (GI) toxicity rate, defined as within 3 months of brachytherapy. Secondary endpoints include acute and late CTCAE toxicity, biochemical failure, patterns of clinical progression, disease-specific and overall survival, and health-related quality of life, as measured by the International Prostate Symptom Score and 26-item Expanded Prostate Cancer Index Composite instruments.
PATIENTS AND METHODS: Key eligibility criteria include: biopsy confirmed LRR prostate adenocarcinoma after prior definitive radiation therapy using any radiotherapeutic modality, no evidence of regional or distant metastasis, and cT1-3a Nx or N0 prostate cancer at initial treatment. All patients will have multiparametric magnetic resonance imaging and molecular PET/CT imaging if possible. In Stage 1, seven patients will be accrued. If there are two or more GI or GU Grade ≥3 toxicities, the study will be stopped. Otherwise, 17 additional patients will be accrued (total of 24 patients). For Stage 2, the cohort will expand to 62 subjects to study the efficacy outcomes, long-term toxicity profile, quality of life, and compare single- vs multi-fraction HDR. Transcriptomic analysis of recurrence biopsies will be performed to identify potential prognostic and predictive biomarkers.
Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
The invention discloses an anti-BASIGN humanized antibody and application thereof, wherein the antibody comprises an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region, and the immunoglobulin light chain variable region comprises a CDR1: as shown in SEQ ID NO. 13 of the sequence table; CDR2: as shown in SEQ ID NO. 14 of the sequence table; CDR3: as shown in SEQ ID NO. 15 of the sequence table; the immunoglobulin heavy chain variable region comprises CDR1: as shown in SEQ ID NO. 16 of the sequence table; CDR2: as shown in SEQ ID NO. 17 of the sequence table; CDR3: as shown in SEQ ID NO. 18 of the sequence Listing. The application of the anti-BASIGIN humanized antibody in preparing medicaments for treating diseases related to CD147 expression.
The invention provides a bioadhesive hydrogel plugging agent for plugging dura mater injury and preventing and treating epidural inflammation fibrosis. The hydrogel plugging agent provided by the invention is used for plugging and tearing the dura mater and simultaneously inhibiting the epidural inflammatory fibrosis. The tannic acid modified BPNS has good environmental stability and antioxidant activity, and can be used for enhancing the performance of ChiDex hydrogel sealant. The invention combines TA@BPNS and ChiDex, and can obtain better mechanical property and dura mater sealing effect. In addition, the ChiDex-TA@BPNS has the capability of scavenging active oxygen, and can effectively inhibit inflammation and fibrosis chain reaction induced by oxidative stress. In vitro and in vivo studies demonstrated that the inflammatory response was relieved after early relief of severe oxidative stress. Progression of epidural fibrosis was also found to be inhibited in the late stages, as evidenced by inhibition of fibroblast activity and ECM deposition.
PURPOSE: Fetal heart diseases significantly contribute to neonatal mortality. Improved prenatal diagnostics enable defect detection before delivery, emphasizing the need for a personalized approach to address anomalies and predict outcomes. Categorizing diseases into risk classes aids obstetricians in counseling and delivery decisions. This study classifies fetal heart diseases by severity, examining factors related to maternal, fetal, and delivery that affect neonatal mortality. The aim is to identify key determinants of neonatal mortality and create an individual approach to assess and manage risks in the first days of a newborn's life.
METHODS: A prospective study from 2019 to 2023 at a tertiary care institute involved pregnant women diagnosed with fetal heart disease. 382 women were categorized into three groups based on potential risk for hemodynamic instability at birth: Group-1 (no or low risk, n = 114), Group-2 (moderate risk, n = 201), and Group-3 (high risk, n = 67). Antenatal follow-up used fetal echocardiography. The study explored the association between maternal-fetal-delivery-related factors and neonatal mortality, with statistical significance set at p < 0.05.
RESULTS: Significant associations with neonatal mortality were found in cases with birth weight < 2500 g (p = 0.002), presence of genitourinary system anomaly (p = 0.001), group-2 and 3 heart disease (p < 0.001), and induction of labor (p = 0.01).
CONCLUSION: Factors influencing neonatal mortality in fetal heart disease cases include heart disease severity (group-3 heart disease), low birth weight, and extracardiac anomalies. While labor induction with prostaglandin ± oxytocin appears to elevate neonatal mortality, this observation requires further validation with larger sample sizes. Obstetricians should consider selective use of prostaglandin for labor induction.
The main purpose was to determine the abundance of dominant phyla, Bifidobacterium spp., and Lactobacillus in breast milk of obese mothers versus normal-weights in fourth month of lactation in Iranian population. Sixty health women at the fourth month of breastfeeding, aged 18-40 years, were included and categorized based on body mass index (BMI) to the obese (BMI ≥ 30 kg/m2) and normal-weights (18.5 ≤ BMI ≤ 24.9). Bacterial DNA was extracted and qPCR of the 16S region was performed after human milk donation in a sterile condition. A multiple linear mixed model was used to determine the effective factors on the phyla population. Bifidobacterium spp. was significantly higher in milk of normal-weight group than the obese. The current weight showed a significant effect on the Actinobacteria abundance in milk. The Bacteroidetes and Firmicutes were significantly lower in mother's milk with cesarean section (p = 0.04). Pre-pregnancy obesity decreased the Firmicutes and Lactobacillus abundance in maternal milk (p = 0.04 and p = 0.01). The Actinobacteria and Bifidobacterium spp. showed a significant effect on infant's height (p = 0.008 and p = 0.04). The maternal current and pre-pregnancy weight showed an important effect on abundance of Actinobacteria and Bifidobacterium spp., as the good phyla and genus in milk which are associated with the infant's height.
PURPOSE:To obtain the reagent having a high sensitivity and good specificity and to stably immobilize the large amt. by immobilizing a Trephonema pallidum (TP) antigen to an antibody in an aq. medium having a prescribe surfactant concn. and a pH value of a specific range. CONSTITUTION:After the TP bacteria cultured in a house rabbit or the like is taken and washed, a surfactant is added thereto and the bacteria are incubat ed. The bacteria are then subjected to bacterium destruction and TP antigen extraction. The liquid is centrifugally separated and the supernatant is collected. The syphilis antigen liquid is prepd. by diluting the supernatant with a surfactant-contg. buffer. The antigen liquid is adjusted to the prescribed surfac tant concn. and pH to prepare the antigen-sensitized liquid. Such antigen- sensitized liquid and a carrier are brought into contact in the aq. medium having about 0.01 to 2.5wt.% surfactant concn. and about pH 4.5 to 7.7 and are incubat ed for a prescribed period of time to immobilize the TP antibody to the carrier. The immobilization of a large amt. of the TP antigen to the carrier with good stability is executed in this way. The syphilis diagnostic reagent having the high sensitivity and the good specificity is obtd. by using such carrier in a method such as, for example, an enzyme immunoassay.
When Intralipid ® is administered, the patients capacity to eliminate the infused fat from the circulation must be monitored by use of an appropriate laboratory determination of serum triglycerides. Overdosage must be avoided. 

During long term intravenous nutrition with Intralipid ®, liver function tests should be performed. If these tests indicate that liver function is impaired, the therapy should be withdrawn. Frequent (some advise daily) platelet counts should be done in neonatal patients receiving parenteral nutrition with Intralipid ®. 

Drug product contains no more than 25 mcg/L of aluminum.

Carcinogenesis, Mutagenesis, Impairment of Fertility. Studies with Intralipid ® have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility. 

Pregnancy Category C: Animal reproduction studies have not been conducted with Intralipid ®. It is also not known whether Intralipid ® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Intralipid ® should be given to a pregnant woman only if clearly needed. 

Nursing Mothers: Caution should be exercised when Intralipid ® is administered to a nursing woman. 

Pediatric Use: See DOSAGE AND ADMINISTRATION. 

AVOID OVERDOSAGE ABSOLUTELY.